Soligenix Inc
Research Soligenix Inc (SNGX) on Bullrun: market cap USD 6.08M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSNGX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 6.08M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 2.82M
- Free cash flow-USD 2.36M
Valuation Snapshot
latest market cap is USD 6.08M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 11.08M | -USD 10.27M | n/a | -2.14 | USD 7.94M | USD 358.14K | USD 5.29M |
| FY2024 | USD 119.37K | -USD 8.27M | -USD 8.40M | 0.0% | -4.98 | USD 7.82M | USD 0 | USD 4.12M |
| FY2023 | USD 839.36K | -USD 6.14M | n/a | 11.6% | -12.66 | USD 8.45M | USD 1.01M | USD 2.52M |
| FY2022 | USD 948.91K | -USD 13.80M | n/a | 42.0% | -4.81 | USD 13.36M | USD 0 | -USD 2.47M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 6.08M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 13.52M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 6.79M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.89M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 19.45M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 28.29M | n/a | n/a | n/a |
About Soligenix Inc
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Soligenix Inc's market cap?
Soligenix Inc's market capitalization is USD 6.08M.
What does Soligenix Inc do?
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions.